News - Lovaza

Filter

Current filters:

Lovaza

Popular Filters

Amarin calls on FDA to extend Vascepa exclusivity by five years

28-02-2014

US biotech firm Amarin has filed with a federal court requesting it to order the US Food and Drug Administration…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLegalLovazaNorth AmericaUSAVascepa

US FDA clears Amarin's Vascepa, a competitor for Lovaza

30-07-2012

The US Food and Drug Administration has approved biotech firm Amarin's (Nasdaq: AMRN) Vascepa (icosapent…

AmarinBiotechnologyCardio-vascularGlaxoSmithKlineLovazaMergers & AcquisitionsNorth AmericaRegulationVascepa

GlaxoSmithKline 1st-qtr 2011 sales and earnings down but firm back in the black; Lovaza subpoena

28-04-2011

After revealing a more than $1 billion loss for the fourth quarter of 2010 as a result of legal charges…

FinancialGlaxoSmithKlineLegalLovazaPharmaceutical

Back to top